Science Current Events | Science News | Brightsurf.com
 

Extra-aggressive form of idiopathic pulmonary fibrosis identified

May 30, 2007
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disorder from which most patients die within 5 years after diagnosis. The disease is characterized by the insidious onset of dyspnea or cough and usually evolves slowly.

Now, Selman and coworkers present in an article published in the online, open-access journal PLoS ONE on Wednesday 30th May, strong evidence indicating that a subset of IPF patients has a short duration of symptoms before diagnosis and display an accelerated clinical course to end-stage disease. The authors postulate that these "rapid progressor" patients, predominantly smoking males, represent a distinct clinical phenotype compared with the usual "slow progressors" patients.

"These findings highlight the variability in the progression and outcome of IPF, and may explain, in part, the difficulty in obtaining significant and reproducible results in studies of therapeutic interventions in patients with IPF," said Dr Selman, who is the Director of Research at the National Institute of Respiratory Research in Mexico City and the lead author on this publication. "They also suggest that physicians should pay more attention to the time of onset of symptoms, and to look for other signs that allow the identification of these rapid progressor patients".

In this study the authors performed global gene expression analysis and other molecular studies in a subset of patients and identified a number of genes that were differentially expressed in both groups, suggesting that rapid progressors are biologically distinct from slow progressors.

"While preliminary, these results may allow investigators to identify biomarkers of disease progression," said Dr King, who is the Chief of Medicine at San Francisco General Hospital and an internationally renowned expert in research and management of pulmonary fibrosis.

The senior author on this paper, Dr Naftali Kaminski, who is the Director of the Simmons Center for Interstitial Lung Disease at the University of Pittsburgh, added that this research highlighted the need to collect as much information on patients with IPF as possible. "We are only now starting to really understand the disease and characterize it," he said, "therefore, it is critical for patients with the disease to be seen in centers that are actively involved in IPF research."

Better identification and understanding of these differences may provide insights into the pathogenesis of IPF and assist in the development of therapeutic interventions for this devastating lung disease.

Public Library of Science


Related Pulmonary Fibrosis Current Events and Pulmonary Fibrosis News Articles


Childhood syndrome combining lung disease, arthritis is identified
Using the latest genome sequencing techniques, a research team led by scientists from UC San Francisco (UCSF), Baylor College of Medicine, and Texas Children's Hospital has identified a new autoimmune syndrome characterized by a combination of severe lung disease and arthritis that currently has no therapy.

Gene in high-altitude cattle disease sheds light on human lung disease
Vanderbilt University researchers have found a genetic mutation that causes pulmonary hypertension in cattle grazed at high altitude, and which leads to a life-threatening condition called brisket disease.

One type of airway cell can regenerate another lung cell type
A new collaborative study describes a way that lung tissue can regenerate after injury.

Premature aging of stem cell telomeres, not inflammation, linked to emphysema
Lung diseases like emphysema and pulmonary fibrosis are common among people with malfunctioning telomeres, the "caps" or ends of chromosomes. Now, researchers from Johns Hopkins say they have discovered what goes wrong and why.

Promising new target may treat pulmonary fibrosis
By uncovering the mechanism by which fibrous tissue cells in the lung multiply, researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA), along with colleagues in Mexico and Canada, have identified a promising new approach for the treatment of pulmonary fibrosis.

Scientists grow 'mini-lungs' to aid the study of cystic fibrosis
Scientists at the University of Cambridge have successfully created 'mini-lungs' using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease.

Outcomes of lung transplantations since implementation of need-based allocation system
Since implementation of a medical need-based allocation system of donor lungs in 2005, double-lung transplantation has been associated with better graft survival than single-lung transplantation in patients with idiopathic pulmonary fibrosis (IPF); at 5 years, there has been no survival difference between single- and double-lung transplant recipients in patients with chronic obstructive pulmonary disease (COPD).

We're all going to die; DNA strands on the end of our chromosomes hint when
BYU biologist Jonathan Alder has a startling secret he doesn't freely share: he knows when most of us are going to die.

Mutations linked to repair of chromosome ends may make emphysema more likely in smokers
Mutations in a gene that helps repair damaged chromosome ends may make smokers -- especially female smokers -- more susceptible to emphysema, according to results of a new study led by Johns Hopkins Kimmel Cancer Center researchers.

Suppressing a protein reduces cancer spread in mice
Scientists have found that decreasing the levels of or blocking a specific protein commonly found in humans and many other animals allowed them to slow the spread of two different kinds of cancer to the lungs of mice.
More Pulmonary Fibrosis Current Events and Pulmonary Fibrosis News Articles

© 2015 BrightSurf.com